13F-HR filed by QIMING U.S. VENTURES MANAGEMENT, LLC
QIMING U.S. VENTURES MANAGEMENT, LLC filed this 13F-HR for the quarter ended 2025-06-30, filed 2025-08-14, with 6 holding rows worth $23,615,986.
- Accession
- 0001415889-25-021900
- Filer
- CIK 1909617
- Filed
- 2025-08-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2025
A holdings report, 6 entries on the cover page, a total value of $23,615,986 stated on the cover page (in dollars after the unit check, H1), rows summing to $23,615,986 with VALUE read as dollars as filed, 13F file number 028-22101. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| Tourmaline Bio Inc | 89157D105 | Common Stock | 741,691 | $11,859,639 | dollars as filed | |
| JASPER THERAPEUTICS INC | 471871202 | COM NEW | 928,964 | $5,155,750 | dollars as filed | |
| KORRO BIO INC | 500946108 | COMMON STOCK | 368,085 | $4,597,382 | dollars as filed | |
| Ventyx Biosciences Inc | 92332V107 | Common Stock | 412,225 | $882,162 | dollars as filed | |
| HILLEVAX INC | 43157M102 | COM | 372,615 | $741,504 | dollars as filed | |
| KEZAR LIFE SCIENCES INC | 49372L209 | COM NEW | 82,871 | $379,549 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001415889-25-021900 | this filing | 2025-08-14 | acceptance time not in the bulk data set |